Reliability and validity of the gastrointestinal symptom rating scale in patients with gastroesophageal reflux disease

被引：41

作者：

Revicki D.A. ^{[1
,2
,5
]}

Wood M. ^{[2
]}

Wiklund I. ^{[3
]}

Crawley J. ^{[4
]}

机构：

[1] MEDTAP International, Inc., Bethesda, MD

[2] University of North Carolina, Chapel Hill, NC

[3] Astra Hassle, Mölndal

[4] Astra Merck Inc., Wayne, PA

[5] MEDTAP International, Inc., Bethesda, MD 20814

来源：

Quality of Life Research | 1997年 / 7卷 / 1期

关键词：

GERD; GSRS; Reliability; Validity;

D O I：

10.1023/A:1008841022998

中图分类号：

学科分类号：

摘要：

The objective of this study was to evaluate the reliability and validity of the Gastrointestinal Symptom Rating Scale (GSRS) in US patients with gastroesophageal reflux disease (GERD). Five hundred and sixteen adults with predominant heartburn symptoms of GERD were recruited from gastroenterologist and family physician practices and treated with 6 weeks of 150 mg ranitidine twice daily to identify poorly responsive symptomatic GERD. The GSRS, the Medical Outcomes Study Short Form-36 (SF-36) Health Survey and the Psychological General Well-being (PGWB) scale were administered at baseline and after 6 weeks of treatment. Reported ratings of GERD-related symptoms from physician and patient diaries were measured. The GSRS contains five scales: reflux syndrome, abdominal pain, constipation syndrome, diarrhoea syndrome and indigestion syndrome. The internal consistency reliabilities for the GSRS scales ranged from 0.61 to 0.83 and the intraclass correlation coefficients ranged from 0.42 to 0.60. The GSRS scale scores were correlated with the SF-36 and PGWB scales and with the number and severity of heartburn symptoms. Patients with two or three clinician-rated GERD-related symptoms reported worse GSRS scale scores compared with patients with fewer symptoms (p < 0.0001). Statistically significant differences in the mean GSRS scale scores were observed between treatment responders and non-responders (p < 0.0001) and patients showing a response to treatment had larger mean changes in their GSRS scales than patients not showing a response to treatment (p < 0.0001). The standardized response means ranged from 0.42 to 1.43 for the GSRS scale scores. It was concluded that the GSRS is a brief, fairly comprehensive assessment of common gastrointestinal symptoms. The GSRS has good reliability and construct validity and the GSRS scales discriminate by GERD symptom severity and are responsive to treatment. The GSRS is a useful patient-rated symptom scale for evaluating the outcomes of treatment for GERD.

引用

页码：75 / 83

页数：8

共 30 条

[1]

Revicki D.A., Health care technology and health-related quality of life, Health Care Technology and Its Assessment: An International Perspective, pp. 114-131, (1993)

[2]

Testa M.A., Simonson D.C., Assessment of quality-of-life outcomes, N Engl J Med, 334, pp. 835-840, (1996)

[3]

Wiklund I., Aspects of quality of life in gastrointestinal disease: Some methodological issues, Scand J Gastroenterol, 30, 208 SUPPL., pp. 129-132, (1995)

[4]

Martin C., Marquis P., Bonfils S., A quality of life questionnaire adapted to duodenal ulcer therapeutic trials, Scand J Gastroenterol, 29, 206 SUPPL., pp. 40-43, (1994)

[5]

Irvine E.J., Quality of life-rationale and methods for developing a disease-specific instrument for inflammatory bowel disease, Scand J Gastroenterol, 28, 199 SUPPL., pp. 22-27, (1993)

[6]

Drossman D.A., Leserman J., Li Z., Et al., The rating form of IBD patients concerns: A new measure of health status, Psychosom Med, 53, pp. 701-712, (1991)

[7]

Chal K.L., Stacey J.H., Sacks G.E., The effect of ranitidine on symptom relief and quality of life of patients with gastrooesophageal reflux disease, Br J Clin Pract, 49, pp. 73-77, (1995)

[8]

Rush D.R., Stelmach W.J., Young T.L., Et al., Clinical effectiveness and quality of life with ranitidine vs placebo in gastroesophageal reflux disease patients: A clinical experience network (CEN) study, J Family Pract, 41, pp. 126-136, (1995)

[9]

Stacey J.H., Miocevich M.L., Sacks G.E., The effect of ranitidine (as effervescent tablets) on the quality of life of GERD patients, Br J Clin Pract, 50, pp. 190-196, (1996)

[10]

Stewart A.L., Greenfield S., Hays R.D., Et al., Functional status and well-being of patients with chronic conditions: Results from the Medical Outcomes Study, JAMA, 262, pp. 907-913, (1989)

← 1 2 3 →